HENRY J FUCHS
CIK 1197355 · President, Worldwide R&D · last filed 2024-09-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$11.81M
Companies
5
Total Filings
195
Lifetime Open-Market Net
-$76.63M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BMRN | President, Worldwide R&D | 185,074 | $63.81 | $11.81M | -$62.29M | 112 | 2024-09-17 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | Director | 10,465 | $58.70 | $614.3K | -$4.81M | 13 | 2023-01-24 |
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 7,833 | — | — | -$2.45M | 29 | 2019-10-03 |
| Ardea Biosciences, Inc./DE (RDEA) Delisted | Director | 0 | — | — | -$1.73M | 20 | 2012-06-20 |
| ONYX PHARMACEUTICALS INC (ONXX) Delisted | EVP & Chief Medical Officer | 14,891 | — | — | -$5.36M | 17 | 2008-11-19 |
Recent Filings · Page 6 of 20
195 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-04-03 | BMRN | Mixed | — | -$463.3K | EDGAR |
| 2018-03-26 | BMRN | Tax (F) | −5,812 | -$472.9K | EDGAR |
| 2018-03-19 | BMRN | Mixed | +11,179 | -$406.2K | EDGAR |
| 2018-03-06 | BMRN | Tax (F) | −2,576 | -$205.7K | EDGAR |
| 2018-02-28 | BMRN | Grant (A) | +20,324 | $0 | EDGAR |
| 2018-01-22 | Mirati Therapeutics, Inc. (MRTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-01-04 | BMRN | Mixed | — | -$831.4K | EDGAR |
| 2018-01-03 | GENOMIC HEALTH INC (GHDX) Delisted | Grant (A) | +292 | $10.0K | EDGAR |
| 2017-10-13 | BMRN | Other (J) | — | $0 | EDGAR |
| 2017-10-03 | GENOMIC HEALTH INC (GHDX) Delisted | Grant (A) | +311 | $10.0K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.